Home / Healthcare/ AstraZeneca’s key lung cancer drug wins European panel thumbs-up

AstraZeneca’s key lung cancer drug wins European panel thumbs-up


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 31 July 2018 00:00


Reuters: AstraZeneca’s cancer drug Imfinzi has won a key recommendation from a European Medicines Agency (EMA) panel less than six months after the first global approvals in Western markets.

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

While final approvals are up to the European Commission, it generally follows the CHMP’s recommendation and endorses them within a couple of months.

The US Food and Drug Administration (FDA) in February granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

Japan also approved the drug earlier this month.

The latest green light - which had been expected after positive clinical data last year - gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Globally, about 30% of patients with NSCLC present with stage III disease. These individuals typically receive a combination of chemotherapy and radiotherapy, but only around 15% of them are still alive after five years.

Imfinzi, chemically known as durvalumab, belongs to a new class of immuno-oncology drugs that block a mechanism tumors use to evade detection from the immune system.

AstraZeneca’s drug already had approval for treating certain patients with bladder cancer. However, this market is relatively small.

The really big opportunity for all companies seeking to exploit the power of modern immuno-oncology drugs is lung cancer, since it is the leading cause of cancer deaths.

Bristol-Myers Squibb, Roche and Merck all have approved products for treating certain patients with advanced lung cancer - but AstraZeneca is now in a position to carve out a niche in treating earlier stage III patients.


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Assessment of fitness and propriety of directors and officers

Friday, 13 December 2019

In the early ’80s, a businessman turned financier from the hill capital started a public deposit canvassing drive by offering 20% interest per month. The depositors were offered on the spot payment of 20% as interest for the first month for their d


How to select top officials to public corporations

Friday, 13 December 2019

It is commendable that the President wants to select suitable decision-makers to public corporations without them being mere and ad hoc political appointments. However, the process thus far seems somewhat weak. Various people are complaining about th


De-stigmatising sexuality education for gender equality – it is a right

Friday, 13 December 2019

International Day for the Elimination of Violence against Women, which fell on 25 November, started the 16 Days of Activism against Gender-Based Violence. It is an annual international campaign that runs for 16 days until 10 December (Human Rights


Presidency and Sangha: virtuous or villainous duo?

Thursday, 12 December 2019

President GR should be ever indebted to the Sangha, because without its tireless canvassing he would not have achieved what he did on 16 November. Given the volatile ethno-religious cleavages and unpredictably shifting alliances in the country, it wa


Columnists More